IL6 and COVID-19: In our study, patients with SARS-CoV-2 infection had lower levels of inflammatory markers such as CRP, procalcitonin, and IL-6 compared to non-COVID-19 patients, suggesting that reduced inflammatory burden may contribute to the higher cholesterol and LPC levels observed in this group.